Ozagrel sodium (ozagrel), a thromboxane A2 synthesis inhibitor, is used for patients with noncardioembolic stroke in China, Korea, and Japan. In the Japanese guideline for managing patients with acute ischemic stroke, it is recommended to start administering ozagrel for patients with noncardioembolic ischemic stroke, including atherothrombotic stroke and lacunar infarction, within 5 days after onset, using a dose of 80?mg twice a day for 14 days[1-2].
(E/Z)-Ozagrel (sodium) [(E/Z)-OKY-046 (sodium)] is an EZ configuration mixture of Ozagrel (sodium) (HY-B0428A). Ozagrel (sodium) is a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel (sodium) is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM[1].
[1] Tomoki Wada MD, Hideo Yasunaga MD et al. “Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis.” Journal of Stroke Cerebrovascular Diseases 25 12 (2016): Pages 2828-2837.
[2] Hiroshi Magara. “Fasudil hydrochloride and ozagrel sodium combination therapy for patients with aneurysmal subarachnoid hemorrhage: a cross-sectional study using a nationwide inpatient database.” Journal of Pharmaceutical Health Care and Sciences 10 1 (2024): 49.
